EGFR and cancer: As a result, the therapeutic index, which is the ratio of IT doses that cause toxic versus therapeutic effects, or the therapeutic window, which is the range of IT dosages that can effectively treat cancer without exerting toxic effects, of anti-EGFR ITs should be improved further [11].